Corporate GovernanceApr 30, 2026, 04:26 PM
RKDA Amends 10-K to Include Part III Info on Governance, Comp
AI Summary
Arcadia Biosciences, Inc. filed an Amendment No. 1 on Form 10-K/A to its Annual Report for the year ended December 31, 2025, to include previously omitted Part III information. This amendment provides details on directors, executive officers, corporate governance, and executive compensation. Key compensation figures for 2025 were disclosed, including Thomas J. Schaefer's total compensation of $300,001 and former CFO Mark Kawakami's $218,425, with no executive bonuses paid for 2025 due to a terminated business combination. The filing also outlined non-employee director compensation and noted the elimination of director meeting attendance fees starting in 2026.
Key Highlights
- RKDA filed Form 10-K/A to include Part III information on governance and compensation.
- Thomas J. Schaefer's 2025 total compensation was $300,001.
- Mark Kawakami's 2025 total compensation was $218,425.
- No executive bonuses were paid for 2025 due to a terminated business combination.
- Non-employee directors received cash compensation, e.g., Kevin Comcowich $90,500 in 2025.
- Director meeting attendance fees were eliminated starting 2026.
- Thomas J. Schaefer serves as President, CEO, and Interim CFO.
- Mark Kawakami resigned as CFO effective September 12, 2025.
Price Impact
More from RKDA